Selective adenosine A2A antagonism through the modulation of basal ganglia function via opposing dopamine D2 receptors seems to be effective for the treatment of PD motor symptoms as a monotherapy or an adjunct therapy to dopaminergic agents [36, 37]. Here, DRD2 is linked to Parkinson disease.